At SEB's Nordic Seminar, CFO Larsen highlighted how management spent 2025 broadly derisking the equity story and laying out the plans for 2026, with focus on executing the ph2 randomised trial in glioblastoma (data in H1/27), adding data in head & neck cancer, and adding a final non-exclusive partnership to support that programme and eventual commercial partnering. Consistent with our estimates, a 2030 launch appears likely, supporting our SEK 101-117 valuation range.
LÄS MER
